Resources
Get the latest information on
developments in ATTR-CM care
Actor portrayals.
Attruby Resources
Patient Brochure
A detailed guide with information on ATTR-CM, treatment options, and support resources to empower patients in managing their health.
Download
Medisafe Flashcard
A quick reference guide offering step-by-step instructions on using Medisafe for seamless medication management.
Download
Patient Resources
Visit the online hub for educational tools, support programs, and links to helpful services for patients navigating their ATTR-CM journey.
Learn More
Additional Information on Variant ATTR-CM
Learn more about variant ATTR-CM, who is primarily affected by this subtype, and how to identify it.
Download
Attruby in Patients With Variant ATTR-CM
Learn more about the efficacy and safety of Attruby in patients with variant ATTR-CM.
DownloadATTR-CM=transthyretin amyloid cardiomyopathy.
Indication and Important safety information
INDICATION
Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were
reported in patients treated with Attruby versus placebo,
respectively. The majority of these adverse reactions were mild and
resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean
decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was
observed in the
adults with ATTR-CM treated with Attruby versus placebo,
respectively, at Day 28 and then stabilized. These changes were
reversible after treatment discontinuation.
Use in Specific Populations
Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.
Please see Full Prescribing Information including Patient Information.
INDICATION AND IMPORTANT
SAFETY INFORMATION
INDICATION
Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were
reported in patients treated with Attruby versus placebo,
respectively. The majority of these adverse reactions were mild and
resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean
decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was
observed in the
adults with ATTR-CM treated with Attruby versus placebo,
respectively, at Day 28 and then stabilized. These changes were
reversible after treatment discontinuation.
Use in Specific Populations
Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.
Please see Full Prescribing Information including Patient Information.